Evidence map›Paper›PMID 20228943›Full record

ArticlePhytochemistry letters2010

The continuing search for antitumor agents from higher plants.

Li Pan, Heebyung Chai, A Douglas Kinghorn

Abstract read
In one paragraph

Article in Phytochemistry letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Current issues in molecular biology · 2021
    Article
  5. Review
  6. Cytotoxic Flavonoids from the Leaves and Twigs ofMolecules (Basel, Switzerland) · 2021
    Article
  7. Cell cycle arrest and apoptosis induction byFood science & nutrition · 2021
    Article
  8. Review
  9. Network Pharmacology-Based Study on the Mechanism of Aloe Vera for Treating Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  10. Juniperus communis extract induces cell cycle arrest and apoptosis of colorectal adenocarcinoma in vitro and in vivo.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Extract ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  16. Article
  17. Article
  18. The complete chloroplast genome of the endangered speciesMitochondrial DNA. Part B, Resources · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Li PanDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, OH 43210, USA.
Heebyung Chai
A Douglas Kinghorn

Funding

Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JAMES R FUCHS · 2007 to 2026
$27.2M
PLANT SELECTION, COLLECTION AND PROJECT DATA MANAGEMENTU19CA052956 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KINGHORN, ALAN DOUGLAS · 1995 to 2004
$4.4M
NCI NIH HHS P01 CA125066NCI NIH HHS U19 CA052956
6 · The paper itself

Abstract

Plant secondary metabolites and their semi-synthetic derivatives continue to play an important role in anticancer drug therapy. In this short review, selected single chemical entity antineoplastic agents from higher plants that are currently in clinical trials as cancer chemotherapy drug candidates are described. These compounds are representative of a wide structural diversity. In addition, the approaches taken toward the discovery of anticancer agents from tropical plants in the laboratory of the authors are summarized. The successful clinical utilization of cancer chemotherapeutic agents from higher plants has been evident for about half a century, and, when considered with the promising pipeline of new plant-derived compounds now in clinical trials, this augurs well for the continuation of drug discovery research efforts to elucidate additional candidate substances of this type.

Identifiers

PMID20228943
PMCPMC2836022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.